Rhoen Klinikum AG (ETR:RHK) has been given a consensus rating of “Sell” by the nine ratings firms that are currently covering the stock, MarketBeat reports. Five analysts have rated the stock with a sell recommendation and four have issued a hold recommendation on the company. The average twelve-month target price among brokerages that have issued ratings on the stock in the last year is €22.09 ($25.68).
A number of analysts have recently weighed in on the company. Commerzbank set a €19.00 ($22.09) target price on Rhoen Klinikum and gave the company a “sell” rating in a research note on Friday, November 16th. Berenberg Bank set a €23.50 ($27.33) price objective on Rhoen Klinikum and gave the stock a “neutral” rating in a research report on Wednesday, November 14th. Independent Research set a €24.00 ($27.91) price objective on Rhoen Klinikum and gave the stock a “neutral” rating in a research report on Tuesday, November 13th. Cfra set a €22.00 ($25.58) price objective on Rhoen Klinikum and gave the stock a “sell” rating in a research report on Monday, November 12th. Finally, Warburg Research set a €25.20 ($29.30) price objective on Rhoen Klinikum and gave the stock a “neutral” rating in a research report on Friday, November 9th.
Shares of ETR:RHK traded up €0.02 ($0.02) during midday trading on Wednesday, reaching €22.24 ($25.86). The company’s stock had a trading volume of 46,516 shares, compared to its average volume of 43,281. Rhoen Klinikum has a fifty-two week low of €25.08 ($29.16) and a fifty-two week high of €32.12 ($37.35).
Rhoen Klinikum Company Profile
RHÖN-KLINIKUM Aktiengesellschaft, together with its subsidiaries, builds, acquires, and operates primarily acute-care hospitals in Germany. Its hospitals offer treatment services primarily in the areas of cardiovascular, neurological disorders, oncology, pneumology, orthopedic, accident, and surgeries; rehabilitation and nursing services to the elderly; and thoracic, tumors, and psychosomatic, as well as spinal, column, and joints diseases.
Further Reading: Preferred Stock
Receive News & Ratings for Rhoen Klinikum Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rhoen Klinikum and related companies with MarketBeat.com's FREE daily email newsletter.